Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASP2998 Monotherapy and Combination Therapy in Advanced Solid Tumors
NCT07287995Phase 2Recruiting
- Sponsor
- Astellas Pharma
- Start
- Feb 2026
- Primary completion
- Jun 2029
- Modality
- Antibody-Drug Conjugates (ADCs)
- Countries
- 2
01
Overview
A Phase 2 trial of ASP2998 in solid tumor, urothelial carcinoma (UC), non-small cell lung cancer (NSCLC), gastric cancer (GC), gastroesophageal junction cancer, sponsored by Astellas Pharma. Started Feb 2026; status: recruiting.
02
Drugs
ASP2998
03
Conditions
solid tumorurothelial carcinoma (UC)non-small cell lung cancer (NSCLC)gastric cancer (GC)gastroesophageal junction cancer
Beyond the preview
Go deeper on NCT07287995.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07287995.